Alzamend Neuro Phase 1/2A AL001 lithium fMRI data wins poster slot at SfN Neuroscience 2026
ALZN•SfN poster slot for Phase 1/2A AL001 results
Alzamend Neuro secured a Neuroscience 2026 poster slot for Phase 1/2A neuroimaging results on AL001, an organic lithium salt.
Findings have not been presented yet; the poster is scheduled for Nov. 18, 2026 in Washington.
Data indicate AL001 treatment was associated with measurable shifts in brain network activity over time.
Management framed the dataset as supporting evidence of brain engagement, adding to prior blood and tissue lithium observations from the trial.
